Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 6,517 shares of Natera stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the sale, the insider owned 197,257 shares in the company, valued at $63,424,043.21. This represents a 3.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
John Fesko also recently made the following trade(s):
- On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The stock was sold at an average price of $267.99, for a total transaction of $79,057.05.
- On Tuesday, July 28th, John Fesko sold 931 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $236,539.17.
- On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18.
Natera Price Performance
Natera stock opened at $326.26 on Friday. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $343.18. The company has a market capitalization of $47.03 billion, a price-to-earnings ratio of -239.90 and a beta of 1.51. The firm's fifty day moving average price is $285.07 and its 200 day moving average price is $233.61.
Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. During the same period in the prior year, the company posted ($0.74) EPS. The firm's revenue for the quarter was up 37.7% on a year-over-year basis. Analysts forecast that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Trust Co. of Vermont acquired a new position in Natera during the 2nd quarter worth $26,000. Reflection Asset Management bought a new position in shares of Natera in the fourth quarter worth $29,000. Elevation Wealth Partners LLC acquired a new position in shares of Natera during the second quarter valued at $30,000. Palladiem LLC acquired a new position in shares of Natera during the fourth quarter valued at $31,000. Finally, Horizon Investments LLC bought a new stake in shares of Natera during the third quarter valued at about $32,000. 99.90% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on NTRA. JPMorgan Chase & Co. boosted their price objective on Natera from $315.00 to $360.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Piper Sandler upped their price target on Natera from $249.00 to $363.50 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Natera in a research note on Friday, July 17th. Leerink Partners set a $330.00 price objective on shares of Natera in a report on Friday, August 7th. Finally, UBS Group set a $260.00 target price on shares of Natera in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $319.38.
Read Our Latest Stock Analysis on Natera
Natera Company Profile
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
